Uniqsis expands LED photoreactor range3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.
Uniqsis announces its PhotoSyn high-power photoreactor light module for continuous flow chemistry is now available with alternative LED array configurations that makes it compatible with a broader range of photochemical reactions.
The availability of three new alternative switchable LED configurations (blue, UVA-blue and blue-green-white) provides chemists with the unique ability to optimally undertake almost any photochemistry reaction. The operating wavelengths of the three LED array configurations are blue (455 nm), blue-green-white (455 nm, 530 nm and 420-700 nm) and UVA-blue (365 nm and 455 nm).
The curved, water-cooled LED arrays in the PhotoSyn are designed to maximise photon intensity and concentrate the available light on the independently temperature controlled central coil reactor. These high-quality LED’s have lifetimes of several years in continuous use without suffering a significant reduction in intensities.
The PhotoSyn incorporates a cooling fan to minimise undesirable radiative heating of the flow reactor whilst being cleverly engineered to completely prevent potentially hazardous light emissions from the unit, thereby avoiding the need to operate the instrument in a shielded enclosure. Moreover, the PhotoSyn is protected with safety interlocks that deactivate the light source and protect the user if any attempt is made to remove the cover whilst in use.
The PhotoSyn is compatible with both the Uniqsis Cold Coil standalone reactor module and the Polar Bear Plus Flow cryogenic flow reactor, which control the coil reactor temperature independently of the lamps. Reactions may be run from 150 °C down to sub-ambient temperatures dependent upon the power of the cooling unit used. The variable power supply allows the lamp power output to be adjusted from 10-100% making the unit suitable for both small scale R&D and scale up applications.
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation